Momentum is growing for Remplir™ in nerve-sparing prostate cancer surgery, with around 100 surgeries now performed using the flagship nerve repair device.
Adoption among Australian urologists is accelerating, with Remplir being used to support postoperative nerve protection and recovery. Surgeons are applying the collagen wrap during robotic-assisted radical prostatectomy with the aim of improving erectile function and urinary continence following surgery.
This emerging application represents a significant commercial opportunity, with the potential to expand Orthocell’s U.S. total addressable market from US$1.6B to approximately US$2B.
To support this opportunity, Orthocell is setting up a commercialisation advisory board and investing in further research to strengthen the scientific evidence base for this new application of Remplir.
Initial clinical performance data from nerve-sparing procedures using Remplir across Australia will be released once compiled.
Orthocell CEO and MD, Paul Anderson, said:
“We’re thrilled to see Remplir being adopted by urologists in Australia for nerve-sparing prostate surgery, reflecting its broader potential in peripheral nerve protection and repair. This demonstrates the utility of the product and represents the potential for a meaningful step forward in improving patient outcomes following these complex surgeries.”